RecruitingNCT06850038
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Studying Alagille syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ipsen
- Principal Investigator
- Ipsen Medical, DirectorIpsen
- Enrollment
- 30 enrolled
- Eligibility
- All sexes
- Timeline
- 2025 – 2029
Study locations (8)
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- UCSF Pediatric Gastroenterology, San Francisco, California, United States
- The Children's Mercy Hospital, Kansas City, Missouri, United States
- Columbia University, New York, New York, United States
- NYU Langone - NYU Grossman School of Medicine, New York, New York, United States
- Le Bonheur Children's Hospital, Memphis, Tennessee, United States
- UT Southwestern Childrens Medical Center, Dallas, Texas, United States
- Proactive El Paso,LLC, El Paso, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06850038 on ClinicalTrials.govOther trials for Alagille syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07411716Pediatric Evaluation and Registry for Liver Cholestasis in CanadaChildren's Hospital of Eastern Ontario
- RECRUITINGNCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)Takeda
- RECRUITINGPHASE4NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)Mirum Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT05035030Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeAlbireo, an Ipsen Company